ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
ABOUT US
NEWS
INVESTOR RELATIONS
简
繁
EN
简
繁
EN
COMPANY NEWS
EssexBio has climbed 13 places over the previous year in “China Pharmaceutical Industry Top 100 Series List” & Beifushu® awarded “China Pharmaceutical Brands List” for the sixth consecutive year
2024.06.27
Essex Bio-Technology (1061.HK) 2023 Annual Results at a glance
2024.03.19
Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%
2024.03.18
Change of Address of Head Office and Principal Place of Business in Hong Kong
2024.01.03
Time
Last 7 days
Last 30 days
The last six months
Date
Title
2021-04-20
Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia
2021-04-07
Preservative-free Unit-dose Moxifloxacin Hydrochloride Eye Drops Obtained Approval from NMPA for Commercilisation in China
2021-03-19
Essex-Biotechnology Announces Bevacizumab Has Received IND Approval from US FDA for the Treatment of wAMD
2021-03-12
Essex Bio-Technology Announces 2020 Financial Results Sales of HK$654m & PAT of HK$170m recorded in 2nd Half
2021-02-24
Essex Bio-Technology and Mitotech announce positive outcome of VISTA-2 Phase 3 clinical study in Dry Eye Disease
2021-01-29
Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia
2020-11-23
Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2020
2020-10-15
Essex and Henlius Entered into a Global Co-Development and Exclusive License Agreement to Jointly Develop Bevacizumab for Treatment of Ophthalmic Diseases
<
2
3
4
5
6
7
8
...
9
>